Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Glucocorticoids and calcineurin inhibitors

5 evidence topics · 4 sources

Immunosuppression in primary and secondary FSGS: KDIGO 2021 glomerular diseases guideline

“Practice Point 6.2.1.1: Immunosuppression should not be used in adults with FSGS of undetermined cause (FSGS-UC), or in those with secondary FSGS.” (opens the source at this quote in a new tab)

“Recommendation 6.2.2.1: We recommend that high-dose oral glucocorticoids be used as the first-line immunosuppressive treatment for primary FSGS (1D).” (opens the source at this quote in a new tab)

“Practice Point 6.2.2.2: Initial high-dose glucocorticoids should be continued until complete remission is achieved, or as tolerated by patients up to a maximum of 16 weeks, whichever is earlier.” (opens the source at this quote in a new tab)

“Recommendation 6.3.1.1: For adults with steroid-resistant primary FSGS, we recommend that cyclosporine or tacrolimus be given for” (opens the source at this quote in a new tab)

“rather than continuing with glucocorticoid monotherapy or not treating (1C).” (opens the source at this quote in a new tab)

“Practice Point 6.3.3.1: Adults with steroid-resistant primary FSGS who respond to CNI treatment should receive CNIs for a minimum of 12 months to minimize the risk of relapses (Figure 55).” (opens the source at this quote in a new tab)

“There is no evidence or a priori rationale justifying the use of glucocorticoids or other immunosuppressive drugs in this population, and the potential for harm of such treatment is clear.” (opens the source at this quote in a new tab)